General abstract submission guidelines
- Abstracts can only be submitted online via the abstract submission form. Abstracts sent by post or email will not be accepted.
- All mandatory fields must be filled out.
- Please choose one of the topics listed below* that best categorizes your abstract. This is important for the reviewing process.
- The maximum length of the abstract is 500 words.
- After the submission deadline it is not possible to make any changes.
- Please ensure correct spelling, grammar and scientific content, as abstracts will be reproduced exactly as submitted. Linguistic accuracy is your responsibility. No proof reading will be done.
- Individuals may be the first author of more than one abstract.
- The presenting author of the abstract must be registered for the meeting.
- Preferably use the following headings in your abstract:
- Background / introduction
- Methods / materials
- Summary / conclusion
- Oral Presentation
will range from 10 to 15 minutes length. Presenting authors should use slides to accompany their presentation.
- Rapid Fire Presentation
Selected abstracts can be presented in Rapid Fire sessions of one slide during one minute.
if your abstract is selected as an poster for the ANR2022 meeting we ask the first authors or a co-author to make themselves available during the breaks and lunch to answer questions.
Please select the topic which best fits with your abstract.
- Genes, genetic defects and dependencies driving neuroblastoma.
- Precision oncology (MYCN, RAS/MAPK, ALK, novel targets, combinatorial drugging, new strategies).
- Genetic heterogeneity in relation to resistance, progression and relapse.
- Phenotypic heterogeneity in relation to resistance, progression and relapse (plasticity, epigenetics).
- Normal development and the origin of neuroblastoma.
- Neuroblastoma biology (metabolism, DNA repair, genomic instability, etc.).
- Preclinical immunology studies and micro-environment.
- Early clinical trials – targeted and other novel therapies.
- Immune therapy (clinical, CART, GD2).
- Relapse treatment (SIOPEN, NANT/COG).
- New developments in surgery and radiotherapy.
- Liquid biopsies, theranostics and imaging.
- Treatment of neuroblastoma in low and middle income countries.